With regard to the Member’s point about the scope of inclusion within the ALN provisions, as he says, there is significant funding committed to support the implementation of the ALN Act and delivery of the wider ALN transformation programme. But the points he raised in the debate today, in particular around the inclusion or exclusion of diabetes, is something I will write to him about if he’s content with that. But I will give him the reassurance that the arrangements that I’m seeking the consent of the Chamber for today are effectively ones that make other legislation work in a way that is consistent with the ALN legislation. So, they’re technical amendments to other legislation, which are consequential to the existing passage of the ALN Bill itself. So, they’re technical in that sense. But if he’s content, I’d be very happy to write to him about the specific points that he’s raised today.